Chemotherapy-induced CDA expression renders resistant non-small cell lung cancer cells sensitive to 5'-deoxy-5-fluorocytidine (5'-DFCR)
CONCLUSIONS: Chemotherapy increases CDA and TYMP expression thereby rendering resistant lung cancer cells susceptible to subsequent 5'-DFCR treatment.PMID:33874986 | DOI:10.1186/s13046-021-01938-2 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - April 20, 2021 Category: Cancer & Oncology Authors: Yanyun Gao Philipp Zens Min Su Camila Anna Gemperli Haitang Yang Haibin Deng Zhang Yang Duo Xu Sean R R Hall Sabina Berezowska Patrick Dorn Ren-Wang Peng Ralph Alexander Schmid Wenxiang Wang Thomas Michael Marti Source Type: research

Biomarkers of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Beyond PD-L1
Clin Lung Cancer. 2021 Mar 24:S1525-7304(21)00060-7. doi: 10.1016/j.cllc.2021.03.006. Online ahead of print.ABSTRACTImmunotherapy has markedly improved the survival rate of patients with non-small cell lung cancer (NSCLC) and has introduced a new era in lung cancer treatment. Although some patients achieve durable responses to checkpoint blockade, not all experience such benefits, and some suffer from significant immunotoxicities. Thus, it is crucial to identify potential biomarkers suitable for screening the population that may benefit from immunotherapy. Based on the current clinical trials, the aim of the present study ...
Source: Clinical Lung Cancer - April 20, 2021 Category: Cancer & Oncology Authors: Luis Cabez ón-Gutiérrez Sara Custodio-Cabello Magda Palka-Kotlowska Soledad Alonso-Viteri Parham Khosravi-Shahi Source Type: research

Molecular diagnosis in non-small-cell lung cancer: expert opinion on ALK and ROS1 testing
J Clin Pathol. 2021 Apr 19:jclinpath-2021-207490. doi: 10.1136/jclinpath-2021-207490. Online ahead of print.ABSTRACTThe effectiveness of targeted therapies with tyrosine kinase inhibitors in non-small-cell lung cancer (NSCLC) depends on the accurate determination of the genomic status of the tumour. For this reason, molecular analyses to detect genetic rearrangements in some genes (ie, ALK, ROS1, RET and NTRK) have become standard in patients with advanced disease. Since immunohistochemistry is easier to implement and interpret, it is normally used as the screening procedure, while fluorescence in situ hybridisation (FISH)...
Source: Clinical Lung Cancer - April 20, 2021 Category: Cancer & Oncology Authors: Esther Conde Federico Rojo Javier G ómez Ana Bel én Enguita Ihab Abdulkader Ana Gonz ález Dolores Lozano Nuria Manche ño Clara Salas Marta Salido Eduardo Salido-Ruiz Enrique de Álava Source Type: research

Select antitumor cytotoxic CD8 < sup > + < /sup > T clonotypes expand in patients with chronic lymphocytic leukemia treated with ibrutinib
CONCLUSIONS: In patients with CLL, established T-cell responses directed against tumor are suppressed by disease and reactivated by ibrutinib.PMID:33875521 | DOI:10.1158/1078-0432.CCR-20-4894 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - April 20, 2021 Category: Cancer & Oncology Authors: Maria Joao Baptista Sivasubramanian Baskar Erika M Gaglione Keyvan Keyvanfar Inhye Ahn Adrian Wiestner Clare Sun Source Type: research

Phase I Study of Muscadine Grape Extract for Patients With Advanced Cancer
CONCLUSIONS: MGE is safe and well-tolerated in heavily pretreated and older cancer patients. The potential anticancer properties and the effects of MGE on physical well-being and QOL metrics will be evaluated in future studies.PMID:33867481 | DOI:10.1097/COC.0000000000000814 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - April 19, 2021 Category: Cancer & Oncology Authors: Rhonda L Bitting Janet A Tooze Scott Isom W Jeffrey Petty Stefan C Grant Rodwige J Desnoyers Alexandra Thomas Christopher Y Thomas Angela T Alistar Shannon L Golden Katherine Pleasant Mark C Chappell E Ann Tallant Patricia E Gallagher Heidi D Klepin Source Type: research

Suitability of endobronchial ultrasound-guided transbronchial needle aspiration samples for programmed death ligand-1 testing in non-small cell lung cancer, the Bristol experience
Asia Pac J Clin Oncol. 2021 Apr 18. doi: 10.1111/ajco.13549. Online ahead of print.ABSTRACTTreatment for non-small cell lung cancer (NSCLC) is now personalised using molecular mutation testing. Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) biopsy suitability for anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR) mutation testing is established. Less is currently known about EBUS-TBNA suitability for PD-L1 (programmed death ligand-1) testing. To assess EBUS-TBNA biopsy adequacy for ALK, EGFR and PD-L1 testing, we conducted a prospective study of 279 consecutive NSCLC ...
Source: Clinical Lung Cancer - April 19, 2021 Category: Cancer & Oncology Authors: Joanna Hardy Nidhi Bhatt Andrew R L Medford Source Type: research

Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score 50
CONCLUSION: Pembrolizumab provides a durable, clinically meaningful long-term OS benefit versus chemotherapy as first-line therapy for metastatic NSCLC with PD-L1 tumor proportion score of at least 50%.PMID:33872070 | DOI:10.1200/JCO.21.00174 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - April 19, 2021 Category: Cancer & Oncology Authors: Martin Reck Delvys Rodr íguez-Abreu Andrew G Robinson Rina Hui Tibor Cs őszi Andrea F ülöp Maya Gottfried Nir Peled Ali Tafreshi Sinead Cuffe Mary O'Brien Suman Rao Katsuyuki Hotta Ticiana A Leal Jonathan W Riess Erin Jensen Bin Zhao M Catherine Pieta Source Type: research

Multisystem Inflammation and Susceptibility to Viral infections in Human ZNFX1 Deficiency
CONCLUSION: ZNFX1 is an important regulator of the response to double-stranded nucleic acids stimuli following viral infections. ZNFX1 deficiency predisposes to severe viral infections and a multisystem inflammatory disease.PMID:33872655 | DOI:10.1016/j.jaci.2021.03.045 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - April 19, 2021 Category: Cancer & Oncology Authors: Stefano Vavassori Janet Chou Laura Eva Faletti Veronika Haunerdinger Lennart Opitz Pascal Joset Christopher J Fraser Seraina Prader Xianfei Gao Luise A Schuch Matias Wagner Julia Hoefele Maria Elena Maccari Ying Zhu George Elakis Michael T Gabbett Maria F Source Type: research

Prognostic Significance of Red Cell Distribution Width in Advanced Non-Small Cell Lung Cancer Patients
The objective of this study was to investigate the significance of RDW in NSCLC patients with EGFR mutations.METHODS: The clinical data of 102 patients with NSCLC who underwent radical resection surgery in the First Affiliated Hospital of Wenzhou Medical University from December 2012 to November 2017 were collected. Kaplan-Meier survival analysis and Cox proportional hazard models were used to examine the effect of RDW on survival.RESULTS: The RDW levels were divided into two groups: high RDW (≥ 13.1%), n = 47 vs. low RDW, n = 55 (
Source: Clinical Lung Cancer - April 18, 2021 Category: Cancer & Oncology Authors: Zhiqiang Zhan Zhenghua Fei Bingying Xu Dian Zhong Dapeng Dong Source Type: research

Prognostic and Diagnostic Values of Circulating Tumor Cells and Tumor Markers for Lung Cancer
CONCLUSIONS: Our data indicate that CTCs are a better choice than TMs for the diagnosis and prognostication of lung cancer.PMID:33865263 | DOI:10.7754/Clin.Lab.2020.200654 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - April 18, 2021 Category: Cancer & Oncology Authors: Xiaoqiang Liu Chenjie Wang Liwen Zhang Haidi Gu Jun Yang Ying Wang Jie Tan Source Type: research

A Novel Automated Immunoassay for Serum NY-ESO-1 and XAGE1 Antibodies in Combinatory Prediction of Response to Anti-Programmed Cell Death-1 Therapy in Non-Small-Cell Lung Cancer
CONCLUSION: Our immunoassay system is useful to predict clinical benefits with NSCLC immune-checkpoint therapy.PMID:33865813 | DOI:10.1016/j.cca.2021.04.008 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - April 18, 2021 Category: Cancer & Oncology Authors: Yumiko Sakai Koji Kurose Kanako Sakaeda Hirotaka Abo Yusuke Atarashi Nobuyuki Ide Toshiyuki Sato Eiichiro Kanda Minoru Fukuda Toru Oga Kenta Noda Mikio Oka Source Type: research

CT-guided microcoil localization for pulmonary nodules in the scapula-shadowed area before Video-Assisted Thoracic Surgery
CONCLUSIONS: CT-guided microcoil technique is a safe and effective localization method prior to VATS for the nodules in the scapula-shadowed area.PMID:33866688 | DOI:10.1111/crj.13379 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - April 18, 2021 Category: Cancer & Oncology Authors: Yanyan Xu Lingchuan Ma Jie Lin Hongliang Sun Zhenguo Huang Zhenrong Zhang Fei Xiao Qianli Ma Source Type: research

Prognostic Significance of Red Cell Distribution Width in Advanced Non-Small Cell Lung Cancer Patients
The objective of this study was to investigate the significance of RDW in NSCLC patients with EGFR mutations.METHODS: The clinical data of 102 patients with NSCLC who underwent radical resection surgery in the First Affiliated Hospital of Wenzhou Medical University from December 2012 to November 2017 were collected. Kaplan-Meier survival analysis and Cox proportional hazard models were used to examine the effect of RDW on survival.RESULTS: The RDW levels were divided into two groups: high RDW (≥ 13.1%), n = 47 vs. low RDW, n = 55 (
Source: Clinical Lung Cancer - April 18, 2021 Category: Cancer & Oncology Authors: Zhiqiang Zhan Zhenghua Fei Bingying Xu Dian Zhong Dapeng Dong Source Type: research

Prognostic and Diagnostic Values of Circulating Tumor Cells and Tumor Markers for Lung Cancer
CONCLUSIONS: Our data indicate that CTCs are a better choice than TMs for the diagnosis and prognostication of lung cancer.PMID:33865263 | DOI:10.7754/Clin.Lab.2020.200654 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - April 18, 2021 Category: Cancer & Oncology Authors: Xiaoqiang Liu Chenjie Wang Liwen Zhang Haidi Gu Jun Yang Ying Wang Jie Tan Source Type: research

A Novel Automated Immunoassay for Serum NY-ESO-1 and XAGE1 Antibodies in Combinatory Prediction of Response to Anti-Programmed Cell Death-1 Therapy in Non-Small-Cell Lung Cancer
CONCLUSION: Our immunoassay system is useful to predict clinical benefits with NSCLC immune-checkpoint therapy.PMID:33865813 | DOI:10.1016/j.cca.2021.04.008 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - April 18, 2021 Category: Cancer & Oncology Authors: Yumiko Sakai Koji Kurose Kanako Sakaeda Hirotaka Abo Yusuke Atarashi Nobuyuki Ide Toshiyuki Sato Eiichiro Kanda Minoru Fukuda Toru Oga Kenta Noda Mikio Oka Source Type: research

CT-guided microcoil localization for pulmonary nodules in the scapula-shadowed area before Video-Assisted Thoracic Surgery
CONCLUSIONS: CT-guided microcoil technique is a safe and effective localization method prior to VATS for the nodules in the scapula-shadowed area.PMID:33866688 | DOI:10.1111/crj.13379 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - April 18, 2021 Category: Cancer & Oncology Authors: Yanyan Xu Lingchuan Ma Jie Lin Hongliang Sun Zhenguo Huang Zhenrong Zhang Fei Xiao Qianli Ma Source Type: research

I κBα targeting promotes oxidative stress-dependent cell death
CONCLUSIONS: NFKBIA amplification and IκBα overexpression identify a unique cancer subtype associated with specific expression profile and metabolic signatures. Through p65-NFKB regulation, IκBα overexpression favors metabolic rewiring of cancer cells and distinct susceptibility to cisplatin. Lastly, we have developed a novel approach to disrupt IκBα/p65 interaction, restoring p65-mediated apoptotic responses to cisplatin due to mitochondria deregulation and ROS-production.PMID:33863364 | DOI:10.1186/s13046-021-01921-x (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - April 17, 2021 Category: Cancer & Oncology Authors: Giovanna Carr à Giuseppe Ermondi Chiara Riganti Luisella Righi Giulia Caron Alessio Menga Enrica Capelletto Beatrice Maffeo Marcello Francesco Lingua Federica Fusella Marco Volante Riccardo Taulli Angelo Guerrasio Silvia Novello Mara Brancaccio Rocco Pia Source Type: research

Neutrophil-Lymphocyte Ratio and Absolute Lymphocyte Count as Prognostic Markers in Patients Treated with Curative-intent Radiotherapy for Non-small Cell Lung Cancer
The objective of this study was to examine the association of NLR/ALC before and after curative-intent radiotherapy for NSCLC on disease recurrence and overall survival.MATERIALS AND METHODS: A retrospective study of consecutive patients who underwent curative-intent radiotherapy for NSCLC across nine sites in the UK from 1 October 2014 to 1 October 2016. A multivariate analysis was carried out to assess the ability of pre-treatment NLR/ALC, post-treatment NLR/ALC and change in NLR/ALC, adjusted for confounding factors using the Cox proportional hazards model, to predict disease recurrence and overall survival within 2 yea...
Source: Clinical Lung Cancer - April 17, 2021 Category: Cancer & Oncology Authors: A Punjabi E Barrett A Cheng A Mulla G Walls D Johnston J McAleese K Moore J Hicks K Blyth M Denholm L Magee D Gilligan S Silverman M Qureshi H Clinch M Hatton L Philipps S Brown M O'Brien F McDonald C Faivre-Finn C Hiley M Evison Source Type: research

Precision oncology in metastatic colorectal cancer - from biology to medicine
Nat Rev Clin Oncol. 2021 Apr 16. doi: 10.1038/s41571-021-00495-z. Online ahead of print.ABSTRACTRemarkable progress has been made in the development of biomarker-driven targeted therapies for patients with multiple cancer types, including melanoma, breast and lung tumours, although precision oncology for patients with colorectal cancer (CRC) continues to lag behind. Nonetheless, the availability of patient-derived CRC models coupled with in vitro and in vivo pharmacological and functional analyses over the past decade has finally led to advances in the field. Gene-specific alterations are not the only determinants that can...
Source: Clinical Lung Cancer - April 17, 2021 Category: Cancer & Oncology Authors: Federica Di Nicolantonio Pietro Paolo Vitiello Silvia Marsoni Salvatore Siena Josep Tabernero Livio Trusolino Rene Bernards Alberto Bardelli Source Type: research

I κBα targeting promotes oxidative stress-dependent cell death
CONCLUSIONS: NFKBIA amplification and IκBα overexpression identify a unique cancer subtype associated with specific expression profile and metabolic signatures. Through p65-NFKB regulation, IκBα overexpression favors metabolic rewiring of cancer cells and distinct susceptibility to cisplatin. Lastly, we have developed a novel approach to disrupt IκBα/p65 interaction, restoring p65-mediated apoptotic responses to cisplatin due to mitochondria deregulation and ROS-production.PMID:33863364 | DOI:10.1186/s13046-021-01921-x (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - April 17, 2021 Category: Cancer & Oncology Authors: Giovanna Carr à Giuseppe Ermondi Chiara Riganti Luisella Righi Giulia Caron Alessio Menga Enrica Capelletto Beatrice Maffeo Marcello Francesco Lingua Federica Fusella Marco Volante Riccardo Taulli Angelo Guerrasio Silvia Novello Mara Brancaccio Rocco Pia Source Type: research

Neutrophil-Lymphocyte Ratio and Absolute Lymphocyte Count as Prognostic Markers in Patients Treated with Curative-intent Radiotherapy for Non-small Cell Lung Cancer
The objective of this study was to examine the association of NLR/ALC before and after curative-intent radiotherapy for NSCLC on disease recurrence and overall survival.MATERIALS AND METHODS: A retrospective study of consecutive patients who underwent curative-intent radiotherapy for NSCLC across nine sites in the UK from 1 October 2014 to 1 October 2016. A multivariate analysis was carried out to assess the ability of pre-treatment NLR/ALC, post-treatment NLR/ALC and change in NLR/ALC, adjusted for confounding factors using the Cox proportional hazards model, to predict disease recurrence and overall survival within 2 yea...
Source: Clinical Lung Cancer - April 17, 2021 Category: Cancer & Oncology Authors: A Punjabi E Barrett A Cheng A Mulla G Walls D Johnston J McAleese K Moore J Hicks K Blyth M Denholm L Magee D Gilligan S Silverman M Qureshi H Clinch M Hatton L Philipps S Brown M O'Brien F McDonald C Faivre-Finn C Hiley M Evison Source Type: research

Precision oncology in metastatic colorectal cancer - from biology to medicine
Nat Rev Clin Oncol. 2021 Apr 16. doi: 10.1038/s41571-021-00495-z. Online ahead of print.ABSTRACTRemarkable progress has been made in the development of biomarker-driven targeted therapies for patients with multiple cancer types, including melanoma, breast and lung tumours, although precision oncology for patients with colorectal cancer (CRC) continues to lag behind. Nonetheless, the availability of patient-derived CRC models coupled with in vitro and in vivo pharmacological and functional analyses over the past decade has finally led to advances in the field. Gene-specific alterations are not the only determinants that can...
Source: Clinical Lung Cancer - April 17, 2021 Category: Cancer & Oncology Authors: Federica Di Nicolantonio Pietro Paolo Vitiello Silvia Marsoni Salvatore Siena Josep Tabernero Livio Trusolino Rene Bernards Alberto Bardelli Source Type: research

Long-Term Survival of Over 6 Years with Afatinib Sequential Treatment in a Patient with EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Case Report
Clin Drug Investig. 2021 Apr 16. doi: 10.1007/s40261-021-01025-6. Online ahead of print.NO ABSTRACTPMID:33861418 | DOI:10.1007/s40261-021-01025-6 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - April 16, 2021 Category: Cancer & Oncology Authors: Hai-Yan Tu Yang-Si Li Jin-Ji Yang Hua-Jun Chen Ben-Yuan Jiang Wen-Zhao Zhong Xue-Ning Yang Yi-Long Wu Source Type: research

Palliative Thoracic Radiotherapy for Non-Small Cell Lung Cancer in Outpatients: Reasons for Unplanned Hospitalization and Its Impact on Survival
CONCLUSIONS: Unplanned hospitalization occurred frequently in a standard care setting without early involvement of a dedicated palliative team. Patients with preceding hospitalization might represent a group that is particularly vulnerable, thus qualifying for a targeted intervention aiming at continued outpatient care.PMID:33854658 | PMC:PMC8016527 | DOI:10.14740/jocmr4445 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - April 15, 2021 Category: Cancer & Oncology Authors: Carsten Nieder Kristian S Imingen Ellinor Haukland Source Type: research

Transarterial management of advance lung cancer
Jpn J Clin Oncol. 2021 Apr 14:hyab050. doi: 10.1093/jjco/hyab050. Online ahead of print.ABSTRACTPrevious reports on transarterial treatment for lung cancer were reviewed. The bronchial arterial infusion therapy has a long history since 1964. Better local control with less doses of anti-neoplastic agents was warranted by trying transarterial administration to lung and mediastinal tumors. It is reported that both primary and metastatic tumors are fed by bronchial or other systemic arteries. The bronchial arterial embolization for hemoptysis has been introduced for clinical practice since 1973. Hemoptysis by not only benign b...
Source: Clinical Lung Cancer - April 15, 2021 Category: Cancer & Oncology Authors: Shinichi Hori Tatsuya Nakamura Norifumi Kennoki Ikuo Dejima Atsushi Hori Source Type: research

Selective expansion of regulatory T cells using an orthogonal IL-2/IL-2 receptor system facilitates transplantation tolerance
J Clin Invest. 2021 Apr 15;131(8):139991. doi: 10.1172/JCI139991.ABSTRACTAdoptive transfer of Tregs has been shown to improve alloengraftment in animal models. However, it is technically challenging to expand Tregs ex vivo for the purpose of infusing large numbers of cells in the clinic. We demonstrate an innovative approach to engineering an orthogonal IL-2/IL-2 receptor (IL-2R) pair, the parts of which selectively interact with each other, transmitting native IL-2 signals, but do not interact with the natural IL-2 or IL-2R counterparts, thereby enabling selective stimulation of target cells in vivo. Here, we introduced t...
Source: Clinical Lung Cancer - April 15, 2021 Category: Cancer & Oncology Authors: Toshihito Hirai Teresa L Ramos Po-Yu Lin Federico Simonetta Leon L Su Lora K Picton Jeanette Baker Jian-Xin Lin Peng Li Kinya Seo Juliane K Lohmeyer Sara B Wagers Melissa Mavers Warren J Leonard Bruce R Blazar K Christopher Garcia Robert S Negrin Source Type: research

Palliative Thoracic Radiotherapy for Non-Small Cell Lung Cancer in Outpatients: Reasons for Unplanned Hospitalization and Its Impact on Survival
CONCLUSIONS: Unplanned hospitalization occurred frequently in a standard care setting without early involvement of a dedicated palliative team. Patients with preceding hospitalization might represent a group that is particularly vulnerable, thus qualifying for a targeted intervention aiming at continued outpatient care.PMID:33854658 | PMC:PMC8016527 | DOI:10.14740/jocmr4445 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - April 15, 2021 Category: Cancer & Oncology Authors: Carsten Nieder Kristian S Imingen Ellinor Haukland Source Type: research

Transarterial management of advance lung cancer
Jpn J Clin Oncol. 2021 Apr 14:hyab050. doi: 10.1093/jjco/hyab050. Online ahead of print.ABSTRACTPrevious reports on transarterial treatment for lung cancer were reviewed. The bronchial arterial infusion therapy has a long history since 1964. Better local control with less doses of anti-neoplastic agents was warranted by trying transarterial administration to lung and mediastinal tumors. It is reported that both primary and metastatic tumors are fed by bronchial or other systemic arteries. The bronchial arterial embolization for hemoptysis has been introduced for clinical practice since 1973. Hemoptysis by not only benign b...
Source: Clinical Lung Cancer - April 15, 2021 Category: Cancer & Oncology Authors: Shinichi Hori Tatsuya Nakamura Norifumi Kennoki Ikuo Dejima Atsushi Hori Source Type: research

Selective expansion of regulatory T cells using an orthogonal IL-2/IL-2 receptor system facilitates transplantation tolerance
J Clin Invest. 2021 Apr 15;131(8):139991. doi: 10.1172/JCI139991.ABSTRACTAdoptive transfer of Tregs has been shown to improve alloengraftment in animal models. However, it is technically challenging to expand Tregs ex vivo for the purpose of infusing large numbers of cells in the clinic. We demonstrate an innovative approach to engineering an orthogonal IL-2/IL-2 receptor (IL-2R) pair, the parts of which selectively interact with each other, transmitting native IL-2 signals, but do not interact with the natural IL-2 or IL-2R counterparts, thereby enabling selective stimulation of target cells in vivo. Here, we introduced t...
Source: Clinical Lung Cancer - April 15, 2021 Category: Cancer & Oncology Authors: Toshihito Hirai Teresa L Ramos Po-Yu Lin Federico Simonetta Leon L Su Lora K Picton Jeanette Baker Jian-Xin Lin Peng Li Kinya Seo Juliane K Lohmeyer Sara B Wagers Melissa Mavers Warren J Leonard Bruce R Blazar K Christopher Garcia Robert S Negrin Source Type: research

Management of Oligometastasis and Oligoprogression in Patients with Epidermal Growth Factor Receptor Mutation-Positive NSCLC in the Era of Third-Generation Tyrosine Kinase Inhibitors
Clin Lung Cancer. 2021 Mar 16:S1525-7304(21)00056-5. doi: 10.1016/j.cllc.2021.03.004. Online ahead of print.ABSTRACTThis review covers the importance of local consolidative therapy (LCT) in patients with epidermal growth factor receptor (EGFR) mutation-positive with oligometastatic and oligoprogressive non-small-cell lung cancer (NSCLC). With the advent of third-generation EGFR tyrosine kinase inhibitors, a more updated review is necessary. We review the efficacy of LCT, pathophysiological background, and treatment modalities other than radiotherapy. In addition, we also discussed when and how LCT should be applied to pati...
Source: Clinical Lung Cancer - April 14, 2021 Category: Cancer & Oncology Authors: Jeong Uk Lim Source Type: research

PD-L1 Expression in Circulating Tumor Cells as a Promising Prognostic Biomarker in Advanced Non-small-cell Lung Cancer Treated with Immune Checkpoint Inhibitors
Clin Lung Cancer. 2021 Mar 16:S1525-7304(21)00057-7. doi: 10.1016/j.cllc.2021.03.005. Online ahead of print.ABSTRACTBACKGROUND: Circulating tumor cells (CTCs) are a promising source of biological information in cancer. Data correlating PD-L1 expression in CTCs with patients' response to immune checkpoint inhibitors (ICIs) in non-small-cell lung cancer (NSCLC) are still lacking.METHODS: This is a prospective single-center cohort study enrolling patients with advanced NSCLC. CTCs were identified and counted with the CellSearch system. PD-L1 expression on CTCs was assessed with phycoerythrin-conjugated anti-human PD-L1 antibo...
Source: Clinical Lung Cancer - April 14, 2021 Category: Cancer & Oncology Authors: Filippo G Dall'Olio Francesco Gelsomino Nicole Conci Laura Marcolin Andrea De Giglio Giada Grilli Francesca Sperandi Francesca Fontana Mario Terracciano Benedetta Fragomeno Nastassja Tober Giulia Manferrari Stefano Brocchi Rita Golfieri Michelangelo Fiore Source Type: research

Computer-Assisted Reporting and Decision Support in Standardized Radiology Reporting for Cancer Imaging
CONCLUSION: These AI-enabled systems are starting to allow information from multiple sources to be integrated and inserted into structured reports to drive improvements in clinical decision support and patient care.PMID:33852324 | DOI:10.1200/CCI.20.00129 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - April 14, 2021 Category: Cancer & Oncology Authors: Bernardo C Bizzo Renata R Almeida Tarik K Alkasab Source Type: research

Selection of Mediastinal Lymphoma Patients for Proton Therapy Within the Proton Collaborative Group Registry: Concordance With the ILROG Guidelines
CONCLUSIONS: Mediastinal lymphoma patients treated with proton therapy are typically young with lower mediastinal involvement. Within a prospective, multi-institutional proton registry, nearly all treated patients fit the ILROG consensus recommendations regarding which mediastinal lymphoma patients may most benefit from proton therapy.PMID:33852456 | DOI:10.1097/COC.0000000000000819 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - April 14, 2021 Category: Cancer & Oncology Authors: Yolanda D Tseng Mark Pankuch Pranshu Mohindra Lisa McGee Carl Rossi Stella Flampouri Carla Hajj Jason K Molitoris John H Chang Henry Tsai Craig Stevens Lane Rosen Carlos Vargas William Hartsell Source Type: research

TYK2 is a prognostic biomarker and associated with immune infiltration in the lung adenocarcinoma microenvironment
CONCLUSION: Our results indicated that TYK2 was a biomarker and associated with prognosis and immune infiltration in LUAD, laying a foundation for further study about the role of TYK2 in the carcinogenesis and progression of LUAD.PMID:33852776 | DOI:10.1111/ajco.13569 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - April 14, 2021 Category: Cancer & Oncology Authors: Aoxiao He Rongguiyi Zhang Jiakun Wang Zhihao Huang Wenjun Liao Yong Li Cong Wang Jun Yang Qian Feng Linquan Wu Source Type: research

Management of Oligometastasis and Oligoprogression in Patients with Epidermal Growth Factor Receptor Mutation-Positive NSCLC in the Era of Third-Generation Tyrosine Kinase Inhibitors
Clin Lung Cancer. 2021 Mar 16:S1525-7304(21)00056-5. doi: 10.1016/j.cllc.2021.03.004. Online ahead of print.ABSTRACTThis review covers the importance of local consolidative therapy (LCT) in patients with epidermal growth factor receptor (EGFR) mutation-positive with oligometastatic and oligoprogressive non-small-cell lung cancer (NSCLC). With the advent of third-generation EGFR tyrosine kinase inhibitors, a more updated review is necessary. We review the efficacy of LCT, pathophysiological background, and treatment modalities other than radiotherapy. In addition, we also discussed when and how LCT should be applied to pati...
Source: Clinical Lung Cancer - April 14, 2021 Category: Cancer & Oncology Authors: Jeong Uk Lim Source Type: research

PD-L1 Expression in Circulating Tumor Cells as a Promising Prognostic Biomarker in Advanced Non-small-cell Lung Cancer Treated with Immune Checkpoint Inhibitors
Clin Lung Cancer. 2021 Mar 16:S1525-7304(21)00057-7. doi: 10.1016/j.cllc.2021.03.005. Online ahead of print.ABSTRACTBACKGROUND: Circulating tumor cells (CTCs) are a promising source of biological information in cancer. Data correlating PD-L1 expression in CTCs with patients' response to immune checkpoint inhibitors (ICIs) in non-small-cell lung cancer (NSCLC) are still lacking.METHODS: This is a prospective single-center cohort study enrolling patients with advanced NSCLC. CTCs were identified and counted with the CellSearch system. PD-L1 expression on CTCs was assessed with phycoerythrin-conjugated anti-human PD-L1 antibo...
Source: Clinical Lung Cancer - April 14, 2021 Category: Cancer & Oncology Authors: Filippo G Dall'Olio Francesco Gelsomino Nicole Conci Laura Marcolin Andrea De Giglio Giada Grilli Francesca Sperandi Francesca Fontana Mario Terracciano Benedetta Fragomeno Nastassja Tober Giulia Manferrari Stefano Brocchi Rita Golfieri Michelangelo Fiore Source Type: research

Efficacy and safety of (188)Re-HEDP in lung cancer patients with bone metastases: a randomized, multicenter, multiple-dose phase IIa study
CONCLUSIONS: 188Re-HEDP at dose of 40 and 50 MBq/kg was generally effective to alleviate pain and improve QOL in lung cancer patients with painful bone metastases. 188Re-HEDP was safe and well-tolerated.PMID:33847856 | DOI:10.1007/s10147-021-01906-y (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - April 13, 2021 Category: Cancer & Oncology Authors: Ping Chen Jun Li Jicong Gui Congjin Liu Yuankai Wang Guangming Zhang Dayu Kuai Yiwei Wu Zengli Liu Changjing Zuo Zhongwei Lv Yingjian Biao ZhangLi Xingdang Liu Source Type: research

Investigation on potential biomarkers of hyperprogressive disease (HPD) triggered by immune checkpoint inhibitors (ICIs)
Clin Transl Oncol. 2021 Apr 13. doi: 10.1007/s12094-021-02579-9. Online ahead of print.ABSTRACTPURPOSE: This project aimed to survey the clinical characteristics and survivals of hyperprogressive disease (HPD) mediated by immune checkpoint inhibitors (ICIs) in an attempt to explore the potential predictors.METHODS: After searching PubMed, MEDLINE, Google Scholar and Cochrane Library databases, 12 studies incorporating 1766 individuals were enrolled. The data were analyzed with Review manager 5.3 software.RESULTS: The results revealed HPD correlated with previous metastatic sites> 2 (OR = 1.86, 95% CI 1.33-2.59, P = 0.00...
Source: Clinical Lung Cancer - April 13, 2021 Category: Cancer & Oncology Authors: J Liu Q Wu S Wu X Xie Source Type: research

Myeloid cell-derived PROS1 inhibits tumor metastasis by regulating inflammatory and immune responses via IL-10
J Clin Invest. 2021 Apr 13:126089. doi: 10.1172/JCI126089. Online ahead of print.ABSTRACTStimulation of TAM (TYRO3, AXL and MERTK) Receptor Tyrosine Kinases promotes tumor progression through numerous cellular mechanisms. TAM cognate ligands GAS6 and PROS1 (for TYRO3 and MERTK) are secreted by host immune cells, an interaction which may support tumor progression. Here we reveal an unexpected anti-metastatic role for myeloid-derived PROS1, directly suppressing the metastatic potential of lung and breast tumor models. Pros1 deletion in myeloid cells led to increased lung metastasis, independent of primary tumor infiltration....
Source: Clinical Lung Cancer - April 13, 2021 Category: Cancer & Oncology Authors: Avi Maimon Victor Levi-Yahid Kerem Ben-Meir Amit Halpern Ziv Talmi Shivam Priya Gabriel Mizraji Shani Mistriel-Zerbib Michael Berger Michal Baniyash Sonja Loges Tal Burstyn-Cohen Source Type: research

An Automated Correction Algorithm (ALPACA) for ddPCR Data Using Adaptive Limit of Blank and Correction of False Positive Events Improves Specificity of Mutation Detection
CONCLUSIONS: Correction of PIFs and application of an adaptive LoB increases specificity without a loss of sensitivity in ddPCR, leading to a higher accuracy in a real-life cohort of patients with stage IV NSCLC.PMID:33842952 | DOI:10.1093/clinchem/hvab040 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - April 12, 2021 Category: Cancer & Oncology Authors: Daan C L Vessies Theodora C Linders Mirthe Lanfermeijer Kalpana L Ramkisoensing Vincent van der Noort Robert D Schouten Gerrit A Meijer Michel M van den Heuvel Kim Monkhorst Daan van den Broek Source Type: research

Correction to: Letter regarding, "Association between the use of aspirin and risk of lung cancer: results from pooled cohorts and Mendelian randomization analyses"
J Cancer Res Clin Oncol. 2021 Apr 11. doi: 10.1007/s00432-021-03636-0. Online ahead of print.NO ABSTRACTPMID:33842990 | DOI:10.1007/s00432-021-03636-0 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - April 12, 2021 Category: Cancer & Oncology Authors: Aayah Nounu Venexia Walker Rebecca C Richmond Source Type: research

An Automated Correction Algorithm (ALPACA) for ddPCR Data Using Adaptive Limit of Blank and Correction of False Positive Events Improves Specificity of Mutation Detection
CONCLUSIONS: Correction of PIFs and application of an adaptive LoB increases specificity without a loss of sensitivity in ddPCR, leading to a higher accuracy in a real-life cohort of patients with stage IV NSCLC.PMID:33842952 | DOI:10.1093/clinchem/hvab040 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - April 12, 2021 Category: Cancer & Oncology Authors: Daan C L Vessies Theodora C Linders Mirthe Lanfermeijer Kalpana L Ramkisoensing Vincent van der Noort Robert D Schouten Gerrit A Meijer Michel M van den Heuvel Kim Monkhorst Daan van den Broek Source Type: research

Correction to: Letter regarding, "Association between the use of aspirin and risk of lung cancer: results from pooled cohorts and Mendelian randomization analyses"
J Cancer Res Clin Oncol. 2021 Apr 11. doi: 10.1007/s00432-021-03636-0. Online ahead of print.NO ABSTRACTPMID:33842990 | DOI:10.1007/s00432-021-03636-0 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - April 12, 2021 Category: Cancer & Oncology Authors: Aayah Nounu Venexia Walker Rebecca C Richmond Source Type: research

Osimertinib-induced Syndrome of Inappropriate Secretion of Antidiuretic Hormone
Clin Lung Cancer. 2021 Mar 16:S1525-7304(21)00055-3. doi: 10.1016/j.cllc.2021.03.003. Online ahead of print.NO ABSTRACTPMID:33839042 | DOI:10.1016/j.cllc.2021.03.003 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - April 11, 2021 Category: Cancer & Oncology Authors: Tomoaki Takao Kentaro Tanaka Yoshimasa Shiraishi Keiichi Ota Yasuto Yoneshima Eiji Iwama Isamu Okamoto Source Type: research

A multi-institutional analysis of fractionated versus single-fraction stereotactic body radiotherapy (SBRT) in the treatment of primary lung tumors: a comparison between two antipodal fractionations
CONCLUSION: SF and TF seems to be equally safe and effective in the treatment of primary inoperable lung tumors especially for smaller lesion. The SF may be preferentially offered to reduce patient access to hospital with no negative impact on tumor control and survival.PMID:33840047 | DOI:10.1007/s12094-021-02619-4 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - April 11, 2021 Category: Cancer & Oncology Authors: F Alongi L Nicosia V Figlia V De Sanctis R Mazzola N Giaj-Levra C Reverberi M Valeriani M F Osti Source Type: research

The impact of treatment facility type on the survival of brain metastases patients regardless of the primary cancer type
This study aimed to investigate the impact of receiving treatment at academic centers on the overall survival (OS) of cancer patients with brain metastases (BMs) regardless of the primary cancer site.METHODS: This retrospective analysis of the National Cancer Database (NCDB) included patients diagnosed with non-small cell lung cancer, small-cell lung cancer, other types of lung cancer, breast cancer, melanoma, colorectal cancer, and kidney cancer and had brain metastases at the time of diagnosis. The data were extracted from the de-identified file of the NCDB, a joint program of the Commission on Cancer of the American Col...
Source: Clinical Lung Cancer - April 10, 2021 Category: Cancer & Oncology Authors: Saber Amin Michael Baine Jane Meza Chi Lin Source Type: research

The impact of treatment facility type on the survival of brain metastases patients regardless of the primary cancer type
This study aimed to investigate the impact of receiving treatment at academic centers on the overall survival (OS) of cancer patients with brain metastases (BMs) regardless of the primary cancer site.METHODS: This retrospective analysis of the National Cancer Database (NCDB) included patients diagnosed with non-small cell lung cancer, small-cell lung cancer, other types of lung cancer, breast cancer, melanoma, colorectal cancer, and kidney cancer and had brain metastases at the time of diagnosis. The data were extracted from the de-identified file of the NCDB, a joint program of the Commission on Cancer of the American Col...
Source: Clinical Lung Cancer - April 10, 2021 Category: Cancer & Oncology Authors: Saber Amin Michael Baine Jane Meza Chi Lin Source Type: research

The impact of treatment facility type on the survival of brain metastases patients regardless of the primary cancer type
This study aimed to investigate the impact of receiving treatment at academic centers on the overall survival (OS) of cancer patients with brain metastases (BMs) regardless of the primary cancer site.METHODS: This retrospective analysis of the National Cancer Database (NCDB) included patients diagnosed with non-small cell lung cancer, small-cell lung cancer, other types of lung cancer, breast cancer, melanoma, colorectal cancer, and kidney cancer and had brain metastases at the time of diagnosis. The data were extracted from the de-identified file of the NCDB, a joint program of the Commission on Cancer of the American Col...
Source: Clinical Lung Cancer - April 10, 2021 Category: Cancer & Oncology Authors: Saber Amin Michael Baine Jane Meza Chi Lin Source Type: research

What Does a Cardio-oncology Service Offer to the Oncologist and the Haematologist?
Clin Oncol (R Coll Radiol). 2021 Apr 5:S0936-6555(21)00103-5. doi: 10.1016/j.clon.2021.03.012. Online ahead of print.ABSTRACTCardio-oncology is an emerging subspecialty arising from the need for multidisciplinary collaboration to address the increasing prominence of cardiovascular disease (CVD) among cancer patients. This overview outlines the case for establishing cardio-oncology services and defines the ways in which these services benefit cancer patients. The primary objective of cardio-oncology is to manage CVDs in order to allow cancer patients to complete the best cancer treatments safely and with minimal interruptio...
Source: Clinical Lung Cancer - April 9, 2021 Category: Cancer & Oncology Authors: M S Andres J Pan A R Lyon Source Type: research

Which Bone-Modifying Agent is Associated with Better Outcomes in Patients with Skeletal Metastases from Lung Cancer? A Systematic Review and Network Meta-analysis
CONCLUSION: In this comprehensive synthesis of all available randomized controlled trial evidence guiding the pharmacologic treatment of bone metastases from lung cancer, denosumab was ranked above zoledronic acid for overall survival and time to SRE and was not different for reducing the incidence of SRE. Both were superior to no treatment for each of these outcomes. Given this, we encourage physicians to consider the use of denosumab or zoledronic acid in treating this patient population. The combination of ibandronate and systemic therapy was the most effective at reducing pain because of metastases. No cost-effectivene...
Source: Clinical Lung Cancer - April 9, 2021 Category: Cancer & Oncology Authors: Anthony Bozzo Jiawen Deng Umaima Abbas Richa Bhasin Marisa Deodat Sajid Wariach Stephanie Sanger Daniel Axelrod Karim Masrouha Robert Turcotte David Wilson Michelle Ghert Source Type: research